maymetsi 50 mg/1000 mg filmsko obložene tablete
metformin; sitagliptin - filmsko obložena tableta - metformin 780 mg / 1 tableta sitagliptin50 mg / 1 tableta; sitagliptin 50 mg / 1 tableta - metformin in sitagliptin
maymetsi 50 mg/850 mg filmsko obložene tablete
metformin; sitagliptin - filmsko obložena tableta - metformin 662,9 mg / 1 tableta sitagliptin50 mg / 1 tableta; sitagliptin 50 mg / 1 tableta - metformin in sitagliptin
maymetsi 50 mg/850 mg filmsko obložene tablete
metformin; sitagliptin - filmsko obložena tableta - metformin 662,9 mg / 1 tableta sitagliptin50 mg / 1 tableta; sitagliptin 50 mg / 1 tableta - metformin in sitagliptin
eprocliv 50 mg/1000 mg filmsko obložene tablete
metformin; sitagliptin - filmsko obložena tableta - metformin 780 mg / 1 tableta sitagliptin50 mg / 1 tableta; sitagliptin 50 mg / 1 tableta - metformin in sitagliptin
eprocliv 50 mg/850 mg filmsko obložene tablete
metformin; sitagliptin - filmsko obložena tableta - metformin 662,9 mg / 1 tableta sitagliptin50 mg / 1 tableta; sitagliptin 50 mg / 1 tableta - metformin in sitagliptin
sitagliptin / metformin hydrochloride mylan
mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabetes mellitus, tip 2 - zdravila, ki se uporabljajo pri diabetesu - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. , trojna kombinacija terapija), kot dodatek k prehrani in vadbi pri bolnikih neustrezno nadzorovano na maksimalno dopustne odmerek metforminom in sulfonil sečnine. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.
belformin 850 mg filmsko obložene tablete
belupo, d.o.o., ljubljana - metformin - filmsko obložena tableta - metformin 662,9 mg / 1 tableta - metformin
belformin 500 mg filmsko obložene tablete
belupo, d.o.o., ljubljana - metformin - filmsko obložena tableta - metformin 390 mg / 1 tableta - metformin
qtrilmet
astrazeneca ab - metformin hidroklorid, saxagliptin, dapagliflozin - diabetes mellitus, tip 2 - zdravila, ki se uporabljajo pri diabetesu - qtrilmet je navedeno pri odraslih, starih 18 let in več, z vrsto 2 sladkorna bolezen:za izboljšanje glycaemic nadzora, ko je z metforminom ali brez sulfonil sečnine (su) in bodisi saxagliptin ali dapagliflozin ne zagotavlja primerne glycaemic nadzor. ko se že zdravijo z metforminom in saxagliptin in dapagliflozin.
glubrava
takeda pharma a/s - metformin hidroklorid, pioglitazone hidroklorid - diabetes mellitus, tip 2 - zdravila, ki se uporabljajo pri diabetesu - glubrava je naveden kot drugi vrstici zdravljenje tip-2 sladkorne bolezni odraslih bolnikov, zlasti prekomerne bolniki, ki ne morejo doseči zadostno glycaemic nadzor na njihovo maksimalno odmerkom ustni metformin sam. po začetku terapije z pioglitazone, bolnike je treba pregledati in po treh do šestih mesecih, da oceni ustreznost odziva na zdravljenje (e. zmanjšanje hba1c). pri bolnikih, ki ne kažejo ustrezen odgovor, pioglitazone, je treba prekiniti,. v luči možnih tveganj z dolgotrajna terapija, predpisovalce morajo potrditi na kasnejše redne preglede, da je korist pioglitazone je ohranjena.